Company
Headquarters: Toronto, ON, Canada
Employees: 2
CEO: Dr. Joseph Edward Tucker Ph.D.
$3.1 Million
USD as of July 1, 2025
| Company | Market Cap (USD) | 
|---|---|
| Novo Nordisk | $309.91 B | 
| Vertex Pharmaceuticals Incorporated | $117.36 B | 
| CSL Limited | $95.75 B | 
| Regeneron Pharmaceuticals, Inc. | $59.14 B | 
| Marinomed Biotech AG | $58.56 B | 
| Company | Market Cap (USD) | 
|---|---|
| Lilly | $699.59 B | 
| Johnson & Johnson | $374.29 B | 
| AbbVie | $336.94 B | 
| Novo Nordisk | $309.91 B | 
| UnitedHealth Group | $279.90 B | 
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.
Enveric Biosciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ENVB wb_incandescent